Navigation Links
Trovagene, Inc. Announces Closing of $15 Million Registered Direct Offering of Common Stock
Date:7/31/2013

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today announced that it has closed a registered direct offering of $15 million of common stock at a price of $7.00 per share.  The shares were sold directly to an institutional investor by the Company.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene intends to use the net proceeds from the offering to fund its research and development activities and for working capital and other general corporate purposes.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-186196), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 4, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov.

About Trovagene, Inc.Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

Chief Financial OfficerAmy Caterina

Investor RelationsTrovagene, Inc.Trovagene, Inc.858-952-7594858-952-7593szaniboni@trovagene.comacaterina@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
2. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
3. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
4. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
5. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
6. CryoLife Announces First European Implant Of HeRO Graft
7. North South Holdings Inc. Announces its First Settlement and License Agreement.
8. Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
9. BioDrain Announces Medical Advisory Board Comprised of Top Doctors and Healthcare Executive
10. NeuroSigma Announces FDA Approval to Commence Phase III Trial
11. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... , Jan. 18, 2017  Magnetic Insight Inc., ... entered into an agreement with inviCRO LLC to ... MPI imaging system based on inviCRO,s VivoQuant™ visualization ... distributed as a complete MPI solution package with ... nanoparticle or cell imaging in vivo. ...
(Date:1/19/2017)... 18, 2017 The drug delivery technology market ... from USD 1,179.20 billion in 2016, at a CAGR ... of chronic diseases, increasing demand for biologics, technological advancements, ... growth of this market. Whereas, self-administration & home care ... significant growth opportunities for players operating in this market. ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from over fifteen ... surgery. Covering topics from cosmetic breast augmentation to breast reconstruction for ...
(Date:1/18/2017)... ... 18, 2017 , ... From a health perspective, 2017 will clearly be the ... to chronic disease, mental health and general physical well-being. The New York Times suggested ... consider. , For one Charlottesville restaurant, good gut health is clearly on the menu. ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, a ... endurance training and fundraising team, to compete in the Boston Marathon on April 17. ... finish the world’s oldest annual marathon to join Team V and support the Foundation’s ...
(Date:1/18/2017)... , ... January 18, 2017 , ... At Hallmark Nameplate, ... announce that they have achieved certification to ISO 13485. This certification is another way ... up to date products and services that they need. , The ISO 13485 Certification ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... of the revolutionary Active Brake Technology (ABT), an innovative braking system that allows ... Active Brake Technology addresses one of the biggest concerns of beginner and intermediate ...
Breaking Medicine News(10 mins):